NCT00879411

Brief Summary

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
670

participants targeted

Target at P75+ for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

April 9, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 10, 2009

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2010

Completed
2.4 years until next milestone

Results Posted

Study results publicly available

May 15, 2012

Completed
Last Updated

March 28, 2014

Status Verified

February 1, 2014

Enrollment Period

9 months

First QC Date

April 9, 2009

Results QC Date

January 18, 2012

Last Update Submit

February 28, 2014

Conditions

Hypertension

Outcome Measures

Primary Outcomes (2)

  • Efficacy (Change of Systolic Blood Pressure)

    Change from baseline in 24h systolic blood pressure (BP) at week 8

    baseline to 8 weeks

  • Efficacy (Change of Diastolic Blood Pressure)

    Change from baseline in 24h diastolic blood pressure (BP) at week 8

    baseline to 8 weeks

Secondary Outcomes (1)

  • Overall Tolerability Scale

    8 weeks

Study Arms (1)

arterial hypertension

Drug: Micardis

Interventions

MicardisDRUG
arterial hypertension

Eligibility Criteria

Age18 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

hypertensive patients

You may qualify if:

  • Patients who have recently been diagnosed with hypertension

You may not qualify if:

  • None (according to investigator)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Interventions

Telmisartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title
Boehringer Ingelheim Call Center
Organization
Boehringer Ingelheim Pharmaceuticals
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Study Officials

  • Boehringer Ingelheim

    Boehringer Ingelheim

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2009

First Posted

April 10, 2009

Study Start

April 1, 2009

Primary Completion

January 1, 2010

Last Updated

March 28, 2014

Results First Posted

May 15, 2012

Record last verified: 2014-02